Norway · Delayed Price · Currency is NOK Orkla ASA Earnings Call Transcripts
Fiscal Year 2026
-
The AGM reviewed strong 2025 financial results, approved a NOK 6 per share dividend, and passed all board proposals, including capital reduction and auditor change. Strategic focus remains on growth, portfolio simplification, and sustainability, with new board members elected and a shareholder proposal on plastic waste rejected.
Fiscal Year 2025
-
Q4 saw 4.5% organic growth and 17% EBIT adjusted increase, with all major segments except Foods contributing positively. Jotun and Orkla Snacks delivered strong profit growth, while inflation and competitive pressures remain key risks.
-
Q3 saw 4.4% organic growth, 9% EPS increase, and NOK 17.9B revenue. Portfolio companies showed mixed performance, with Jotun and Orkla India as key contributors. A NOK 4B share buyback was announced, and raw material costs are expected to stabilize in 2025.
-
Organic growth reached 3.8% with strong performance in Fuel Ingredients and Home & Personal Care, while Health and Snacks faced margin pressures from high input costs. Portfolio simplification and a potential India IPO progressed, with EBIT margin and return on capital employed both improving.
-
Delivered strong TSR and financial improvements, reduced portfolio complexity, and advanced strategic priorities for organic growth, simplification, and targeted M&A. Portfolio companies are on track for 2026 targets, with operational enhancements and ESG progress supporting long-term value creation.
-
Solid quarterly results with 2% revenue growth, 10% EBIT (adjusted) increase, and 19% higher EPS year-over-year. Margin improvements were broad-based, though snacks and foods faced volume declines due to high cocoa prices and inventory adjustments. Portfolio simplification and cost-saving initiatives continued.
Fiscal Year 2024
-
Strong EBIT and cash flow growth in 2024, driven by portfolio simplification, margin improvements, and stable market shares. Cocoa price volatility and asset sales shaped the quarter, with a proposed NOK 10 per share dividend reflecting robust performance.
-
Q3 delivered strong profit and margin growth, with adjusted EPS up 10% and EBIT up 17% year-over-year. Organic growth was broad-based, cash flow improved, and key segments like Jotun and Orkla Health outperformed, despite inflation and cocoa price pressures.
-
Q2 saw 7% EPS growth and 13% EBIT Adjusted growth, with strong margin expansion and positive volume trends across most segments. Portfolio simplification advanced with asset sales, while input costs and private label competition remain key watchpoints.